Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Jason David Sawyer purchased 240,000 shares of Greenland Mines Ltd. Common Stock stock in a transaction that occurred on Wednesday, July 22nd. The shares were bought at an average price of $0.23 per share, for a total transaction of $55,200.00. Following the completion of the transaction, the director owned 240,000 shares in the company, valued at $55,200. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Greenland Mines Ltd. Common Stock Price Performance
Shares of Greenland Mines Ltd. Common Stock stock opened at $0.19 on Thursday. Greenland Mines Ltd. Common Stock has a one year low of $0.16 and a one year high of $1.08. The business’s 50 day simple moving average is $0.27 and its two-hundred day simple moving average is $0.37. The stock has a market capitalization of $26.24 million, a P/E ratio of -0.59 and a beta of 7.05.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.15) earnings per share for the quarter.
Institutional Trading of Greenland Mines Ltd. Common Stock
Analysts Set New Price Targets
GRML has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a report on Saturday, May 2nd. Weiss Ratings upgraded shares of Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Greenland Mines Ltd. Common Stock presently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on GRML
About Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Read More
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
